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Abstract The term “catastrophic” antiphospholipid syndrome
(CAPS) is used to define a subset of the antiphospholipid
syndrome (APS) characterized by the clinical evidence of three
or more organ involvement by thrombotic events in a short
period of time and with laboratory confirmation of the
presence of antiphospholipid antibodies. We describe a male
infant first admitted at 17 days old for necrotizing enteritis
complicated by cardiac and renal failure. Because of progres-
sive renal function deterioration, a renal biopsy was performed
at 8 months old, and histopathologic examination was
compatible with renal venous thrombosis. Laboratory search-
ing for vascular, prothrombotic, and metabolic disease was
negative. Five months later, he developed two different
episodes (20-day range) of ischemic stroke. Genetic test for
thrombophilic conditions was positive for two different
mutations, and repeatedly high titers of lupus anticoagulant,
anticardiolipin, and anti-β2glicoprotein I antibodies were
found. He was treated successfully with anticoagulants and
showed a favorable clinical evolution. To the best of our
knowledge, this is the youngest patient reported with probable
CAPS. Although rare, APS/CAPS in the neonatal period or in
the first year of life must be suspected in infants presenting
with thrombotic phenomena. The present case illustrates the
importance of an early diagnosis and treatment to enhance
possibilities of survival.
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Introduction
The antiphospholipid syndrome (APS) is a noninflamma-
tory autoimmune disorder characterized by the association
of thrombotic phenomena and/or recurrent fetal loss, in
combination with elevated titers of antiphospholipid (aPL)
antibodies [11]. The Sapporo criteria are the most accept-
able diagnostic criteria for APS, and its last revision (2006)
defines one clinical criterion and one laboratory criterion
for its definite diagnosis (Table 1).
Despite the strong association between aPL antibodies and
thrombosis, its pathogenic role in the development of
thrombosis has not been fully elucidated [9]. These antibodies
are not always pathogenic and can be present in several
situations, for example, infections, autoimmune diseases,
tumors, and even in 3–4% of healthy individuals, without
being related to thrombotic phenomena [7]. An unusual
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variant of the APS, termed the “catastrophic” antiphospho-
lipid syndrome (CAPS), was first described by Asherson in
1992, and represents the extreme end of the APS spectrum,
resulting in multiorgan failure [4, 18]. Although CAPS
represents 0.8–1% of all patients with APS, it is usually a
life-threatening medical situation that requires high clinical
awareness [4]. The diagnosis of CAPS is based on the
preliminary criteria for its classification, defined by the
international consensus statement in 2003 (Table 2) [4].
Thrombotic events may present in patients as a free-standing
condition (primary APS) or be associated with other
autoimmune diseases, most commonly systemic lupus
erythematosus (SLE; secondary APS) [5, 10, 12, 18, 20].
There are no prospective studies because of the rarity of the
condition, and CAPS treatment is not currently standardized
[4], but anticoagulation, corticosteroids, plasma exchange,
intravenous gammaglobulins, and immunosuppressant
agents are the most commonly used therapies [7]. Despite
adequate therapy, the mortality remains high, approximately
50%, with cardiac problems as the main cause. Once
recovery has ensued, patients usually have a stable course,
but require continued anticoagulation [2]. A recent study has
documented that 66% of CAPS patients who have survived
the initial catastrophic event had remained symptom free for
an average follow-up of 62.7 months, and 26% developed
further APS-related events; however, there were no instances
of further catastrophic events [8]. Because of pediatric
CAPS’ rarity, only individual case reports or small case
series have been reported in the literature and, therefore, few
information exist on the pediatric aspects and long-term
outcome of this disorder [6, 10].
Case report
We present a male, caucasian neonate from healthy non-
consanguineous parents, labor and delivery at 36th week of
pregnancy, 50th percentile for weight and height, and Apgar
score of 7/9. He was first admitted to the hospital
emergency care at 17 days old with irritability, marked
abdominal distension with tenderness, vomiting and bloody
stool, and signs of shock (delayed capillary refill, persistent
tachycardia, and hypotension). Laboratory findings include
hemoglobin (Hgb) 15.6 g/dl, 22,700 leukocytes/mm3,
500,000 platelets/mm3, C-reactive protein (CRP) 1.26 mg/dl,
and metabolic acidosis (pH, 7.0; HCO3¯, 12 mmol/L;
alkaline excess, −18 mmol/L; lactate, 12.7 mmol/L). The
abdominal ultrasonography showed increased amounts of
intraperitoneal non-loculated purulent fluid and markedly
distended small bowel loops. After stabilization in the
intensive care unit, an exploratory laparotomy was performed.
Extensive small bowel necrosis was found, and resection was
made with ileostomies. The histopathology was compatible
with the small bowel’s transmural infarction (necrotizing
enteritis). After surgery, septic shock evolved to multiorgan
failure, with severe hypotension, cardiac dysfunction, and
profound laboratory abnormalities (Hgb, 9.3 g/dl; 2,200 leu-
kocytes/mm3; 53,000 platelets/mm3; CRP, 35 mg/dl; and
Table 1 Revised classification criteria for the antiphospholipid syndrome (2006)
Antiphospholipid antibody syndrome (APS) is present if at least one of the clinical criteria and one of the laboratory criteria that follow are met
Clinical criteria
(1) Vascular thrombosis
One or more clinical episodes of arterial, venous, or small vessel thrombosis in any tissue or organ. Thrombosis must be confirmed by objective
validated criteria (i.e., unequivocal findings of appropriate imaging studies or histopathology). For histopathologic confirmation, thrombosis
should be present without significant evidence of inflammation in the vessel wall.
(2) Pregnancy morbidity
(a) One or more unexplained deaths of a morphologically normal fetus at or beyond the 10th week of gestation, with normal fetal morphology
documented by ultrasound or by direct examination of the fetus, or
(b) One or more premature births of a morphologically normal neonate before the 34th week of gestation because of: eclampsia or severe
preeclampsia defined according to standard definitions, or recognized features of placental insufficiency, or
(c) Three or more unexplained consecutive spontaneous abortions before the 10th week of gestation, with maternal anatomic or hormonal
abnormalities and paternal and maternal chromosomal causes excluded
Laboratory criteria
(1) Lupus anticoagulant (LA) present in plasma, on two or more occasions, at least 12 weeks apart, detected according to the guidelines of the
International Society on Thrombosis and Haemostasis (Scientific Subcommittee on Las/phospholipid-dependent antibodies)
(2) Anticardiolipin (Acl) antibody of IgG and/or IgM isotype in serum or plasma, present in medium or high titer (> the 99th percentile), on two or
more occasions, at least 12 weeks apart, measured by a standardized ELISA
(3) Anti-β2 glycoprotein-I antibody of IgG and/or IgM isotype in serum or plasma present in medium or high titer (> the 99th percentile), on two
or more occasions, at least 12 weeks apart, measured by a standardized ELISA, according to recommended procedures
Classification of APS should be avoided if less than 12 weeks or more than 5 years separate the positive aPL test and the clinical manifestation.
Coexisting inherited or acquired factors for thrombosis are not reasons for excluding patients from APS trials
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disseminated intravascular coagulation with hepatic
insufficiency), requiring invasive ventilatory and inotro-
pic support. Blood and intra-abdominal fluid cultures
were positive for Escherichia coli. At the fourth day, the
patient became stable and 4 weeks later underwent a
second surgery to assess for viability of the remaining
bowel. Twenty-four hours later, he suddenly developed
shock with severe cardiac failure (dilated myocardiopathy
with decreased ejection fraction of the left ventricle), with
troponin (13.46 ng/mL) and activated partial thromboplas-
tin time (aPTT) (>160 s) elevation. After a period of
hypotension, he developed severe hypertension and
oligoanuric acute renal failure (glomerular filtration rate
(GFR), 16.07 ml/min/1.73 m2) with macroscopic hematu-
ria. The doppler ultrasonography showed an atrophic right
kidney with poor corticomedullary differentiation, with its
main artery not visualized. The patient required continu-
ous venovenous hemodiafiltration for 20 days. Hyperten-
sion (average, 180/110 mmHg) was very difficult to
control requiring a combination of eight antihypertensive
drugs. The abdominal magnetic resonance (MR) angiog-
raphy confirmed the right kidney’s atrophy with marked
hypoperfusion of its main artery, and radionuclide imaging
with 99m Tc-MAG3 showed its severe decreased function
(7%). Screening for hereditary prothrombotic and meta-
bolic diseases was negative (Table 3).
At 6 months old, he was discharged with a delayed
growth, controlled hypertension, left ventricle hypertro-
phy, and mild-to-moderate renal insufficiency (GFR,
32 ml/min/1.73 m2) under conservative treatment. Two
months later, right nephrectomy was performed and
hypertension stabilized. The histopathology documented
a generalized cortical atrophy (Fig. 1), reduction of the
main renal vein and its branches’ lumen by chronic
thromboses, with signs of recanalizing thrombi, and
histological features of fibrous intimal hyperplasia of the
interlobular and small arteries, abnormalities compatible
with renal vein thrombosis, thrombotic microangiopathy,
and subsequent chronic renal ischemia (Fig. 2).
At 13 months old, he presented with focal tonic-clonic
seizures and right hemiparesis. Brain CT revealed an acute
infarct involving the left frontal, temporal, and parietal
lobes, without associated hemorrhage (Fig. 3). He was
treated with acetylsalicylic acid 5 mg/kg/day and pheno-
barbital with improvement, but 20 days later, he developed
left hemiparesis de novo accompanied by axial weakness,
right eye exophoria, and generalized hyperreflexia. Brain
CT and MR angiography showed multiple de novo acute
ischemic infarcts in the frontal, right temporal, and parietal
lobes (Fig. 3). Intracardiac, carotid, and vertebral arteries’
thrombus/masses were excluded by doppler ultrasonogra-
phy. Subcutaneous low-molecular-weight heparin (LMWH)
1 mg/kg/day was added. At that time, genetic test for
thrombophilias showed two different mutations: heterozy-
gosity for prothrombin gene mutation (PT 20210G>A) and
homozygosity for plasminogen activator inhibitor-1 gene
mutation (PAI-1 675G>A). Immunologic studies revealed
positive antinuclear antibody (ANA) titer 1/640 and
positive anticardiolipin (aCL; 1.8 U/mL (<1.1)) and anti-
β2glycoprotein I (anti-β2GPI; IgM, 1.0 U/mL; IgG,
25.1 U/mL (<20)) antibodies (Table 3). Erythrocyte
sedimentation rate was 22 mm/1sth.
At 24 months old, immunologic studies demonstrated
persistent positive ANA titer 1/640, mild positive lupus
Table 2 Criteria for the classification of catastrophic APS by international consensus statement on classification criteria and treatment guidelines
(2003)
(1) Evidence of involvement of three or more organs, systems, and/or tissuesa
(2) Development of manifestations simultaneously or in less than a week
(3) Confirmation by histopathology of small vessel occlusion in at least one organ or tissueb
(4) Laboratory confirmation of the presence of antiphospholipid antibodies (lupus anticoagulant and/or anticardiolipin antibodies)c
Definite catastrophic APS
• All four criteria
Probable catastrophic APS
• All four criteria, except for only two organs, systems, and/or tissues involvement
• All four criteria, except for the absence of laboratory confirmation at least 6 weeks apart due to the early death of a patient never tested for aPL
before the catastrophic APS
• 1, 2, and 4
• 1, 3, and 4 and the development of a third event in more than a week but less than a month, despite anticoagulation
a Usually, clinical evidence of vessel occlusions, confirmed by imaging techniques when appropriate. Renal involvement is defined by a 50% rise
in serum creatinine, severe systemic hypertension (>180/100 mmHg), and/or proteinuria (>500 mg/24 h)
b For histopathological confirmation, significant evidence of thrombosis must be present, although vasculitis may coexist occasionally
c If the patient had not been previously diagnosed as having an APS, the laboratory confirmation requires that presence of antiphospholipids must
be detected on two or more occasions at least 6 weeks apart (not necessarily at the time of the event)
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anticoagulant (LA) (screening test, 47.3 s (<45); confirma-
tory test, 32.4 s (<38)), and positive aCL (5.4 U/mL) and
anti-β2GPI (IgM, 2 U/mL; IgG, >150 U/mL) antibodies.
Three months later, LA, aCL, and anti-β2GPI antibodies
became negative. At that time, the patient’s mother,
previously healthy and with no previous history of fetal
losses or thromboembolic events, was tested negative for
immunologic studies, including aPL antibodies. Addition-
ally, there was no family history of thrombotic disorders or
fetal losses.
A retrospective diagnosis of “probable” CAPS was
made. The clinical evolution was favorable, and after
5 years of follow-up, the patient is asymptomatic while
anticoagulated (LMWH), despite intermittent laboratory
signs of disease’s activity (Table 3) and the residual
sequelae: developmental delay, systemic hypertension, and
mild renal insufficiency.
Discussion
In children, the frequency of aPL-related thrombotic events
is generally lower than in adults, but several common
infections are likely responsible for higher percentage of
nonpathogenic and transient aPL antibodies in childhood
[6]. Nevertheless, most of the clinical features that occur in
adults with aPL antibodies have also been described in
children [6]. In pediatrics, the incidence peak for throm-
botic events occurs in the neonate. The use of central
catheter, asphyxia, septicemia, and dehydration are major
risk factors for thrombosis in most studies [19]. We believe
that the first thrombotic event, and the first manifestation of
APS in this patient, was the small bowel’s transmural
infarction, which took place during his first month of life.
Both thrombosis and APS should be a differential diagnosis
on necrotizing enterocolitis (NEC) at that time, but it was
initially assigned to the prematurity, even being a near-term
infant. Although more common in premature infants, NEC
a 
b 
c 
Fig. 2 a, b Reduction of the main renal vein and its branches’ lumen by
chronic thromboses, with signs of recanalizing thrombi, c histological
features of fibrous intimal hyperplasia of interlobular and small arteries,
abnormalities compatible with renal vein thrombosis, thrombotic
microangiopathy, and subsequent chronic renal ischemia
Fig. 1 Generalized cortical atrophy, with preservation of glomerular
structures (fetal isotype) in more than 2/3 of the cortical thickness
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can occur in term and near-term babies, being its incidence
inversely associated to birth weight and gestational age
[21]. Unfortunately, aPL antibodies were not performed but,
retrospectively, we can reasonably suspect they were
already present at that time. Considering this episode as
the first manifestation of CAPS in this patient, and to the
best of our knowledge, this is the youngest patient (17 days
old) with probable CAPS [13, 17].
According to Asherson, precipitant factors for APS have
been recognized in 45% of patients, most commonly
infections (20%). Other “trigger” factors that have been
reported include trauma and surgical procedures (14%),
drugs (5%), or autoimmune diseases’ flares (3%) [2]. In this
patient, possible precipitant factors could have been: (1)
infection/septic shock preceding the small bowel’s infarc-
tion, (2) the last surgery, and therapeutic procedures he was
submitted during septic shock preceding right renal vein
thrombosis. Both vascular cerebral accidents were not
related to an apparent “trigger” factor.
Special concern is needed when dealing with aPL-
positive children who have other congenital or acquired
prothrombotic risks, and APS patients should be stratified
according to that [6, 16]. This patient had both central lines
and a positive prothrombin gene and PAI-1 mutations,
which probably contributed as additional risk factors for
thrombosis, as it was seen in another infantile APS
published recently [14].
The diagnosis of CAPS is still controversial because of
its recent description and the few number of cases reported
[4]. Clinically, the patients present predominantly with
small vessel occlusions involving parenchymal organs, but
large vessel occlusive disease can also occur [2]. In a series
of 50 patients with CAPS, Asherson et al. reported that the
kidney (78%), lung (66%), and central nervous system
(56%) are the most affected organs [1, 18]. In our patient,
two of these main groups of organs were affected.
Hypertension is a well-documented complication of APS
and CAPS. In the series reported byNochy et al., hypertension
was present in 93% of the APS patients; in some of them, it
was the only clinical sign of nephropathy, and it can be very
difficult to treat [22], as was seen in our patient. In case of
kidney involvement, good control of systemic hypertension
and adequate anticoagulation may have important prognostic
implications in preventing progression to end-stage renal
disease [22]. In our patient, nephrectomy of the atrophic
kidney was necessary to control hypertension because
anticoagulation was postponed until thrombosis has been
confirmed by histopathology. Several other clinical features
are relatively common in these patients, predominantly
during disease’s acute phase, such as thrombocytopenia,
seizures, mesenteric inflammatory vaso-occlusive disease
with secondary small bowel infarctation, intrarenal vascular
lesions (thrombotic microangiophaty), livedo reticularis, or
hemolytic anemia [3, 11, 15, 20]. The first four of these
recognized manifestations associated with CAPS were
present in our patient.
The clinical features depend on which organs are
affected and on the extent of thrombosis [2]. Because of
tissue necrosis, excessive cytokine release leads to a
systemic inflammatory response accountable for some of
the CAPS’ non-thrombotic manifestations, particularly the
acute respiratory distress syndrome (ARDS) and myocar-
dial dysfunction [2]. Our patient never had ARDS, but
myocardial dysfunction complicated by acute cardiac
collapse was present.
The preliminary criteria for CAPS classification define
probable and definite CAPS (Table 2) [4]. Definite CAPS is
considered when all four criteria are met. Our patient
presented as a “probable CAPS” with three of the four
defined criteria: three-organ involvement (small bowel,
right kidney, and brain), histopathologic evidence of
thrombosis (renal vein thrombosis), and positive aCP and
anti-β2GPI antibodies on two occasions at least 6 weeks
apart. The occurrence of different thrombotic episodes
ba 
Fig. 3 a Acute infarct involving
the left frontal, temporal, and
parietal lobes, without associated
hemorrhage, b multiple de novo
acute ischemic infarcts in the
frontal, right temporal, and
parietal lobes
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simultaneously or in less than 1 week was not recognized.
However, Asherson et al. emphasized that these criteria are
mostly empirical, have been accepted for classification
purposes, and are not intended to be used as strict
diagnostic criteria in a given patient [4].
We believe that our patient’s aPL antibodies (aCL and
anti-β2GPI) had been produced de novo by himself instead
of transplacental passage of antibodies from his mother
[19], who was tested negative for aPL antibodies. Addi-
tionally, serum patient’s determination occurred when a
maternal origin for these antibodies would be improbable
(14 and 24 months old).
Lack of prospective and randomized treatment trials has led
to considerable debate on the appropriate management of
children with CAPS [6]. It has three clear aims: to treat any
identifiable precipitating factor, to prevent and treat the
ongoing thrombotic events, and to suppress the excessive
cytokine “storm” [4, 7]. There is a general agreement that
long-term anticoagulation is needed in a child who experi-
enced an aPL-related thrombosis to prevent recurrences, but
there is no consensus about the duration and intensity of this
therapy [6].
In regard to this patient, the hypertension and the renal
failure were considered a consequence of the unexpected renal
vein thrombosis in the first months of life, but his neurologic
sequelae could have been avoided with an earlier diagnosis.
Nevertheless, after 5 years of follow-up under anticoagulation,
he had no more thrombotic events. It is essential to start
treatment as soon as this condition is suspected [7], and we
think that the non-progressing clinical evolution in this
patient was the result of an appropriate treatment initiated as
soon as the diagnosis was established.
Finally, although rare, CAPS in neonatal period or in the
first year of life must be suspected in infants presenting
with thrombotic phenomena, even if they have been born
from a mother without SLE or APS [19].
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